Results 81 to 90 of about 1,870 (108)

From helicobacter pylori to glucose metabolism: can DOB values serve as a predictive marker? [PDF]

Front Med (Lausanne)
Zhou Y, Xu J, Huang Z, He D, Duan H, Shi Y, Wang Z, Chen Z.   +7 more
europepmc   +1 more source

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancer. [PDF]

J Transl Med
Liu Z, Liu M, Chen H, Li S, Zheng N, Xing G, Zhang Y, Xu J, Li M, Xiao C, Lu T, Yan Q, Lei Z, Feng M, Li Y.   +14 more
europepmc   +1 more source

Oncolytic virus therapy for hepatocellular carcinoma: A bibliometric analysis of research landscapes, hotspots, and clinical transformation trends from 2000 to mid-2025. [PDF]

Hum Vaccin Immunother
Yu F, Yin S, Zhu J, Sun K.
europepmc   +1 more source

Swine TRIM25 inhibits vesicular stomatitis virus replication by activation of type I IFN signaling pathway and binding vRNA. [PDF]

J Vet Sci
Cao Y, Zhang J, Yoo D, Zhang H, Jiang D, Hu Y, Cong X, Li J, Wu X, Du Y, Qi J, Huang J.   +11 more
europepmc   +1 more source

Research and Clinical Progress of Therapeutic Tumor Vaccines. [PDF]

Vaccines (Basel)
Dong C, Li Z, Tan D, Sun H, Liang J, Wei D, Zheng Y, Zhang L, Liu S, Zhang Y, Wang J, He Q.   +11 more
europepmc   +1 more source

Oncolytic virus therapy in hepatocellular carcinoma. [PDF]

Oncol Res
Ye Y, Liu Y.
europepmc   +1 more source

Revisiting the Immune Frontier in Soft Tissue Sarcomas. [PDF]

Curr Oncol Rep
Bilani N, Al Akoum N, Al-Marayaty R, Orlando S, Alexiev B, de Viveiros PH, Pollack SM.   +6 more
europepmc   +1 more source

Viral polymerase-host interaction analysis reveals that the association between avian NUP93 and PB1 promotes H5N6 avian influenza virus replication. [PDF]

Microbiol Spectr
Cao L, Wang T, Ren P, Cheng C, Mao H, Hui X, Lin X, Hu X, Sun X, Huang K, Jin M.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Predictive biomarkers for the oncolytic virus, JX-594, through the HIF-dependent interferon beta pathway in metastatic renal cell carcinoma.

Journal of Clinical Oncology, 2023
710 Background: Although combination approaches with an immunotherapy are established as the first-line setting in metastatic renal cell carcinoma (mRCC), immunotherapy are only efficacious for a subset of patients. Our group has been working on improving the benefit of immunotherapy using JX-594 (pexastimogene devacirepvec, Pexa-vec) in mRCC.
Jee Soo Park, Myung Eun Lee, Won Sik Jang, Jongchan Kim, Namhee Lee, Keunhee Oh, Won Sik Ham   +6 more
openaire   +1 more source